A carregar...

Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma

Purpose: This study aimed to identify the survival benefit and safety of alternative dosage schedules for sunitinib in metastatic renal cell carcinoma. Materials and Methods: Clinicopathologic and survival data of patients treated with sunitinib as first-line therapy were retrospectively reviewed. P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Zhang, Xingming, Sun, Guangxi, Zhao, Jinge, Shu, Kunpeng, Zhao, Peng, Liu, Jiandong, Yang, Yaojing, Tang, Qidun, Chen, Junru, Shen, Pengfei, Wang, Jia, Zeng, Hao
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6160671/
https://ncbi.nlm.nih.gov/pubmed/30271490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.25693
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!